Gap junction (GJ)-mediated intercellular communication (GJIC) is a fundamental mechanism for the maintenance of cellular homeostatic balance. Gap junctions are involved in the control of cell proliferation, differentiation, cell death and gene expression among other functions ([@bib15]; [@bib4]). Each GJ channel is formed by two hexameric structures called connexons, each provided by one of the two neighbouring cells. A connexon is composed of six polytopic transmembrane protein subunits termed connexins (Cx) that determine the permeability and regulatory properties of the GJ channel. The molecular cutoff of GJs is ∼1 kDa, allowing the exchange of small metabolites, ions, secondary messengers and small peptides between coupled cells ([@bib13]). Over 21 different isoforms of Cxs have been characterised in humans ([@bib30]), with Cx43 being the most ubiquitously expressed connexin in mammals ([@bib33]).

Connexin gene mutations and/or variations in their expression level or subcellular localisation patterns have been observed in a plethora of human diseases. All of them have, as a common factor, alterations in intercellular communication, apoptosis and proliferation ([@bib24]; [@bib35]; [@bib22]). Decreased or diminished expression and/or function of Cxs have been observed in most tumour cell lines and in solid tissue tumours, including melanoma ([@bib18]; [@bib52]; [@bib12]; [@bib32]). The role of GJs in tumour progression has been studied mainly through the ectopic reintroduction of Cx genes into tumour cell lines. Ectopic expression of Cx43 has been shown to reduce cell proliferation in many distinct cancer cells, including in mouse melanoma cell lines ([@bib17]; [@bib10]; [@bib1]). The mechanisms that may be involved in the inhibition of tumour cell growth by Cx43 re-expression include enhanced sensitivity to cell death, increased propagation of death signals and inhibition of proliferation via the regulation of specific kinases ([@bib19]; [@bib23]; [@bib52]). However, there is limited information about the role of Cx43 expression in cell proliferation/cell death and metastatic capacity in human melanoma. In this regard, [@bib45] observed that overexpression of Cx43 in a malignant melanoma cell line resulted in the suppression of the anchorage-independent growth, suggesting that Cx43 may also be a tumour suppressor gene in human melanoma. Recently, [@bib53] demonstrate that the overexpression of a dominant-negative Cx43 mutant decreases the anchorage-independent growth and increases the invasive potential of human melanoma cells.

In contrast with the established role of Cxs regulating growth of tumour cells in culture, the role of Cxs in tumour cell invasion and metastasis is controversial. Several reports suggest that Cxs might reduce tumour metastasis ([@bib26]; [@bib40]; [@bib3]; [@bib36]; [@bib49]), whereas others argue the opposite effect ([@bib32]; [@bib44]), highlighting cell- and context-specific components of the process. In the present study, we aimed to evaluate the role of Cx43 expression in cell proliferation, apoptosis and metastatic capacity in human melanoma. Using a combination of *in vitro* and *in vivo* assays, we provide new insights into the biology of Cx43 in melanoma, and validate Cx43 as an important factor regulating growth, survival and metastasis formation.

Materials and methods
=====================

Cell culture
------------

DFB, DFW, HF and FMS human melanoma cell lines were established and characterised at the Microbiology and Tumor Biology Center (MTC), Karolinska Institute, Sweden ([@bib39]). The lines were derived from metastatic lesions of patients treated at Radiumhemmet, Karolinska Hospital. DFW is a depigmented melanoma subline obtained from DFB by limiting dilution. Melanoma cells were grown at 37 °C in an atmosphere with 5% CO~2~ in RPMI 1640 culture medium (Invitrogen, Carlsbad, CA, USA), supplemented with 10% foetal bovine serum (FBS), penicillin (100 U l^−1^), streptomycin (100 *μ*g ml^−1^) and 1 *μ*[M L]{.smallcaps}-glutamine. The pIRES-Cx43-transfected cells were grown in the same medium in the presence of geneticin G418 (250 *μ*g ml^−1^; Invitrogen). Cells were incubated with 300 *μ*[M]{.smallcaps} of GJ-inhibitory Cx43-specific mimetic peptide 1848 (CNTQQPGCENVCY, extracellular loop 1; 95% purity), Cx43-specific gap20 control peptide (EIKKFKYGIEEHC, cytoplasmic loop; 95% purity) ([@bib29]) or 5 *μ*[M]{.smallcaps} of the Cx43-specific peptide 5 (P5), which prevent hemichannel opening but do not disrupt GJ communication (VDCFLSRPTEKT, extracellular loop 2; 955 purity) ([@bib34]). Peptides were purchased from GenScript (Piscataway, NJ, USA).

Cell immune fluorescence staining and confocal microscopy
---------------------------------------------------------

Melanoma cells were grown on poly-[L]{.smallcaps}-lysine-coated slides (Sigma-Aldrich, Steinheim, Germany). Cells were washed two times with PBS and fixed with 4% paraformaldehyde (PFA) for 30 min. After gentle washing with PBS, the cells were incubated in ammonium chloride (50 *μ*[M]{.smallcaps}) for 10 min, were permeabilised with 0.5% Triton X-100 for 10 min, and blocked with 0.5% bovine serum albumin (BSA). Cells were then incubated with the anti-Cx43 polyclonal antibody (C6219; Sigma-Aldrich) overnight at 4 °C. Samples were stained with a secondary donkey anti-rabbit FITC-conjugated Ab (Poly4064; BioLegend, San Diego, CA, USA) and 5 *μ*g ml^−1^ Hoechst 33342 (Invitrogen) and mounted using DAKO fluorescence mounting medium. The samples were analysed using a Nikon Eclipse C2si confocal microscope (Plan Apo VC60X OIL DIC N2, NA: 1.4). Images were acquired using the NIS element AR V3.2 software (Nikon, Melville, NY, USA).

Flow cytometry
--------------

Flow cytometry experiments were performed as described previously ([@bib46]). Cells were fixed and permeabilised with Intracellular Fixation and Permeabilisation Buffer Set (BD Pharmingen, San Jose, CA, USA). Subsequently, melanoma cells were incubated with an F(ab)2 rabbit polyclonal anti-Cx43 directed to the C-terminal domain (C6219; Sigma-Aldrich) followed by a secondary donkey anti-rabbit FITC-conjugated Ab (Poly4064; BioLegend). Samples were acquired on a FACSCalibur (BD Biosciences, Franklin Lakes, NJ, USA) and analysed using the FCS Express 4 plus software (DeNovo, Glendale, CA, USA) or FlowJo (version 8.8.6; Tree Star, Ashland, OR, USA).

Cx43 stable transfection
------------------------

FMS cells were transfected using FugeneHD (Roche Diagnostic, Indianapolis, IN, USA), according to the manufacturer\'s instructions, with a empty pIRES vector (Clontech Laboratories, Palo Alto, CA, USA) or containing the CMV promoter controlling the expression of the wild-type Cx43 cDNA, as described previously ([@bib2]). Cells were selected in 250 μg ml^−1^ geneticin G418 (Promega, Madison, WI, USA) 48 h after transfection. Clonal cell populations were obtained by limiting dilution method.

Calcein-AM dye transfer assay
-----------------------------

The calcein-AM dye transfer assay was performed according to a previously described method ([@bib6]). Briefly, donor melanoma cells were loaded with 1 *μ*[M]{.smallcaps} calcein-AM (C-1359; Sigma-Aldrich) and acceptor melanoma cells were loaded with Dil (15 *μ*g ml^−1^; D-282; Molecular Probes, Eugene, OR, USA) for 30 min at room temperature. After thoroughly washing with PBS, both cell types were cocultured at a 1 : 1 ratio (calcein^+^-donor cells : Dil^+^-acceptor cells) for 60 min at 37 °C. Calcein transfer from the donor to the acceptor cells was evaluated by flow cytometry, determining the percentage of calcein^+^ cells among the Dil^+^ cells. Calcein transfer assays were carried out in the presence of the Cx43-specific mimetic peptide 1848, control peptide gap20 or P5.

CFSE cell proliferation assay
-----------------------------

Melanoma cells were synchronised by serum deprivation for 48 h. Thereafter, the cells were labelled with CFSE at a final concentration of 5 *μ*[M]{.smallcaps} (37 °C for 10 min), and cultured in serum-supplemented medium for additional 24 h. Flow cytometric analysis of cell proliferation by CFSE dilution was performed as described previously ([@bib38]).

\[^3^H\]thymidine incorporation assay
-------------------------------------

Melanoma cells were synchronised by serum deprivation for 48 h. Thereafter, the cells were cultured in the presence of serum and proliferation was measured by \[^3^H\]thymidine uptake (Topcount NXT; Perkin-Elmer, Waltham, MA, USA) at 24 h according to standard methods. Proliferation was evaluated in cells untreated or pretreated for 4 h (before \[^3^H\]thymidine addition) and treated every 4 h with 1848 or gap20 peptides.

Western blot
------------

Equal amounts of protein (30 μg) extracted from FMS-EV- or FMS-Cx43-transfected cells were separated by 12% SDS--PAGE followed by electrotransfer to nitrocellulose membranes (Hybond; Amersham Biosciences, Piscataway, NJ, USA). Connexin 43 expression was examined as described ([@bib28]), using an anti-human Cx43 polyclonal antibody (Sigma-Aldrich). Total lysates were probed with anti-*β*-actin antibody (Sigma-Aldrich) as a loading control. Signal was visualised using a chemiluminescence substrate system (Biological Industries, Amersham Biosciences).

Apoptotic cell analysis
-----------------------

FMS-EV- or Cx43-transfected cells were incubated or not with 200 ng ml^−1^ of tumour necrosis factor-*α* (TNF-*α*) for 24 h. Annexin-V and propidium iodide (PI) staining was used to analyse apoptosis according to the manufacturer\'s instructions (Apoalert; Clontech Laboratories Inc.).

Mice
----

Nonobese diabetic/SCID mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA) and kept in filtered cages under pathogen-free conditions in the high security animal facilities of the Institute of Biomedical Science, University of Chile. All experiments requiring animals were approved by the Faculty of Medicine Bioethical Committee and performed according to Home Office Animal Welfare Legislation.

Melanoma cell xenotransplantation and metastasis experiments
------------------------------------------------------------

Eight-week-old NOD/SCID mice (three per group) were subcutaneously injected into the right flank with 5 × 10^5^ FMS, DFB, FMS-EV or FMS-Cx43 cells. Tumour growth was monitored every 2--3 days by measuring the tumour volume with a calliper. Tumour volume was calculated according to the equation: (longer diameter × shorter diameter)^2^/2. For lung metastasis assay, 8-week-old NOD/SCID mice (six per group) were injected with 2.5 × 10^5^ FMS-EV cells, FMS-Cx43 cells or saline solution (100 *μ*l) intravenously into the tail vein. After 18 days, the mice were killed and autopsied to analyse melanoma lung metastasis.

Tumour immunohistochemical and immunofluorescence staining
----------------------------------------------------------

Lungs from animals injected with FMS-EV and FMS-Cx43 cells were fixed with 2% PFA for 12 h at 4 °C, dehydrated with 75% ethanol, rinsed in Xilol and then paraffin-embedded. Next, 3 μm sections were obtained, which subsequently underwent treatment with 0.01 m[M]{.smallcaps} EDTA for antigen retrieval, followed by a 10 min treatment with 3% hydrogen peroxide to block endogenous peroxidase activity. The samples were thereafter washed two times with 0.05% PBS/Tween. Finally, the sections were incubated with 4% BSA/PBS for 30 min and then labelled with anti-cleaved caspase-3 (asp175) antibody (Cell Signalling Technology, Beverly, MA, USA; 1 : 50 dilution), or anti-Melan-A (Mart-1) mouse monoclonal antibody (Dako, Tokyo, Japan; 10 *μ*g ml^−1^), for 1 h at room temperature. The samples were then washed two times with 0.05% Tween/PBS before incubation with the respective secondary peroxidase antibody (Vector Laboratories, Burlingame, CA, USA) for 30 min. Samples were incubated with ABC solution (Vectastain ABC Kit; Vector Laboratories) for 20 min at 37 °C, and revealed with the chromogenic substrate DAB (Vector Laboratories). Human gonadal tissues were used as a positive control and lung tissues from non-injected animals were used as a negative control.

For immunostaining assay, an anti-Cx43 polyclonal antibody (Sigma-Aldrich) was used overnight at 4 °C, followed by incubation with a secondary donkey anti-rabbit Alexa Fluor 488-conjugated antibody (Life Technologies, Carlsbad, CA, USA). Samples were additionally stained with 5 *μ*g ml^−1^ Hoechst 33342 (Invitrogen) and visualised by confocal microscopy (LSM 510; 363 numerical aperture 1.4 oil immersion objective; Carl Zeiss, Jena, Germany).

Statistics
----------

Statistical analyses were performed using the GraphPad Prism 3.0 program (GraphPad Software Inc., San Diego, CA, USA). Differences between experimental and control were tested by applying ANOVA test. Results are expressed as the mean±s.e.m. In all experiments a *P*\<0.05 was considered statistically significant.

Results
=======

Cx43 expression correlates with GJIC in human melanoma cells
------------------------------------------------------------

Connexin 43 expression was analysed in four different human metastatic melanoma cell lines, named FMS, HF, DFW and DFB. Total Cx43 expression was assessed by flow cytometry on permeabilised melanoma cells. As depicted in [Figure 1A](#fig1){ref-type="fig"}, DFW and HF cells showed higher total Cx43 levels compared with FMS and DFW cells. To examine the potential role of Cx43 expression in GJ formation between these cells, we analysed its cellular localisation by immunofluorescence and confocal microscopy. Weak positive Cx43 cytosolic and nuclear staining was observed in all melanoma cell lines analysed ([Figure 1B](#fig1){ref-type="fig"}). However, Cx43 clustering in cell--cell contact areas (white arrows) was only detected in HF cells, indicating the low frequency of occurrence of Cx43-GJ plaques in melanoma cells.

The presence of functional GJIC among melanoma cells was then monitored by calcein-AM transfer assays in the four cell lines ([Figure 2A](#fig2){ref-type="fig"}). Melanoma cells with the lowest levels of Cx43 expression (FMS) had the lowest incidence of dye coupling (FMS: 4.7±0.4% compared with DFW: 6.9±0.8% DFB: 8.3±1.1% HF: 8.6±1%) ([Figure 2A](#fig2){ref-type="fig"}, lower panel). The transfer of calcein-AM was significantly reduced when the cells were cultured in the presence of an inhibitory Cx43-specific mimetic peptide (1848) compared with cells treated with the control gap20 peptide ([Figure 2A](#fig2){ref-type="fig"}, lower panel), indicating that Cx43-GJ channels are required for functional GJIC between these melanoma cells.

Additionally, CFSE dilution assays indicated that FMS melanoma cells with the lowest levels of both Cx43 expression and GJIC displayed the highest rate of *in vitro* cell proliferation, compared with DFW and DFB cells ([Figure 2B](#fig2){ref-type="fig"}).

We then assessed tumour growth rate in NOD/SCID mice xenotransplanted with FMS or DFB, the melanoma cell lines with the lowest and highest Cx43-mediated cell coupling and highest and lowest *in vitro* proliferation levels, respectively. In line with the *in vitro* observations, FMS tumours grew faster than DFB tumours *in vivo* ([Figure 2C](#fig2){ref-type="fig"}).

Cx43 overexpression reduces proliferation rates and increases susceptibility to apoptosis in FMS melanoma cells
---------------------------------------------------------------------------------------------------------------

To address the direct effect of Cx43 in melanoma cell proliferation, Cx43-containing vectors or empty vectors (EV) were stably transfected in FMS cells. Connexin 43 overexpression was confirmed by western blotting and flow cytometric analysis of FMS cells ([Figures 3A and B](#fig3){ref-type="fig"}). Additionally, we analysed Cx43 subcellular localisation by confocal microscopy. As depicted in [Figure 3C](#fig3){ref-type="fig"}, overexpression of Cx43 was associated with the occurrence of Cx43-GJ plaque structures at the cell--cell interface (white arrows), whereas FMS-EV cells showed weak and mainly nuclear Cx43 staining. In accordance with these results, FMS-Cx43 cells showed increased incidence of dye coupling compared with control FMS-EV cells (21.5±2.6 *vs* 6.7±1.8) ([Figure 3D](#fig3){ref-type="fig"}). Dye transfer was markedly reduced when FMS-Cx43 cells were cultured in the presence of peptide 1848, but not in cells treated with the control peptide gap20 or with a Cx43-hemichannel-specific inhibitory peptide (P5) ([Figure 3D](#fig3){ref-type="fig"}).

Connexin 43 overexpression induced a significant reduction in the proliferation rate of FMS cells ([Figure 3E](#fig3){ref-type="fig"}), which was completely reverted after incubation with the inhibitory Cx43-specific mimetic peptide 1848 ([Figure 3E](#fig3){ref-type="fig"}). These data demonstrate that Cx43 expression in melanoma cells regulates their proliferative potential, likely through a mechanism dependent on GJ-mediated intercellular communication.

It has been shown that Cx43 overexpression in prostate cancer cells increases their susceptibility to TNF-*α*-induced apoptosis ([@bib48]). To establish whether Cx43 expression is involved in the control of cell survival in human melanoma cells, we measured the percentage of apoptotic FMS-Cx43 and FMS-EV cells before and after TNF-*α* incubation. Both the basal percentage of early apoptotic cells (annexin-V^+^PI^−^) and total dying cells (annexin-V^+^) were higher in FMS-Cx43 compared with that in FMS-EV cells (5.9±1.7% compared with 3.2±0.4% 11.1±2.3% compared with 6.2±1.3% [Figures 4A--C](#fig4){ref-type="fig"}). Tumour necrosis factor-*α* treatment did not increase the fraction of early apoptotic or total dying cells in FMS-EV ([Figures 4A and B](#fig4){ref-type="fig"}). However, the fraction of early apoptotic cells was increased in FMS-Cx43 treated with TNF-*α* compared with untreated cells (10.2±1.2% *vs* 5.9±1.7% [Figures 4A and B](#fig4){ref-type="fig"}). Taken together, these results show that in addition to a reduction in cell proliferation, Cx43 expression increases basal and TNF-*α*-induced apoptosis in melanoma cells.

Cx43 overexpression reduces melanoma tumour growth and lung metastasis in xenotransplanted mice
-----------------------------------------------------------------------------------------------

To investigate the role of Cx43 expression in melanoma tumour growth and lung metastasis formation *in vivo*, FMS-Cx43 and FMS-EV control cells were injected subcutaneously or intravenously, respectively, in NOD/SCID mice. In line with our *in vitro* observations, we found that Cx43 overexpression significantly deaccelerated tumour growth in xenotransplanted mice ([Figure 5A](#fig5){ref-type="fig"}). In contrast, tumours arising from control melanoma FMS-EV cells grew significantly faster, and mice had to be killed 16 days after inoculation. Similar data were observed in terms of metastatic spread. Whereas FMS-EV melanoma cells gave rise to multiple metastatic pulmonary foci, the highly metastatic potential of the FMS cells was strongly inhibited by overexpression of Cx43 ([Figure 5B](#fig5){ref-type="fig"}). These data illustrate a tumour-intrinsic role of Cx43 in the regulation of melanoma metastatic spread in the absence of an immune response. Moreover, immunohistochemical analysis showed that both the multiple and bigger tumours found in animals inoculated with FMS-EV cells and the less frequent and smaller tumours produced by the FMS-Cx43 injected cells both expressed the melanoma marker Mart-1 ([Figure 5C](#fig5){ref-type="fig"}), ruling out a putative role of Cx43 in the dedifferentiation of melanoma cells *in vivo*. Interestingly, immunostaining showed that FMS-Cx43 metastatic tumours expressed higher levels of both Cx43-based GJs and active caspase-3 *in vivo*, compared with FMS-EV tumours ([Figures 5D and E](#fig5){ref-type="fig"}). Altogether, these results suggest that Cx43 expression in melanoma cells decreases their tumorigenic and metastatic potential influencing both proliferation and survival rates, likely through a GJIC-dependent mechanism.

Discussion
==========

The current study provides direct evidence of the impact of Cx43 expression in human melanoma growth and metastatic behaviour *in vitro* and *in vivo*, at least in the last steps of metastasis formation, that is, extravasation, survival and growth in a distant organ. The tumour suppressor properties of Cx43 may be complex, cancer type-specific and may involve both channel (GJ and hemichannels)-dependent and -independent mechanisms. A recent study in B16-BL6 cells, a mouse melanoma cell line with low levels of Cx43 expression, reported a decreased proportion of cells in the S phase of the cell cycle after Cx43 overexpression ([@bib1]). Inhibition in cell proliferation was further associated with an increase in homocellular GJIC between melanoma cells when cocultured in the presence of keratinocytes, although restoration of heterocellular GJIC was not observed ([@bib1]). These data, along with our current findings, suggest that, through a yet unknown mechanism, Cx43-mediated intercellular communication in melanoma control cell growth and proliferation in both human and murine models.

It has been shown that Cx43 reduces proliferation in glioblastomas, osteosarcoma and ovarian carcinoma by inhibiting cell cycle progression through increased p27 expression and inhibition of the S-phase kinase-associated protein Skp2 ([@bib17]; [@bib52]). Ectopic expression of Cx43 in breast tumour cells induces tumour-suppressive properties through the downregulation of fibroblast growth factor receptor 3 ([@bib37]). Moreover, Cx43 can interact with over 30 distinct proteins, including proteins with a tumour suppressor role such as caveolin 1 ([@bib25]) and CCN3 ([@bib11]; [@bib41]).

Key molecules associated with cell proliferation/survival and which are permeable to Cx43 channels include NAD^+^, ATP, Ca^2+^, IP~3~, glutathione and prostaglandin E2 ([@bib7]). Accordingly, it has been shown that inhibition of Cx43 channels by 18-*β*-glycyrrhetinic acid induces cell proliferation by modulating intracellular ATP and Ca^2+^ levels ([@bib43]). Intracellular Ca^2+^ signalling and the generation of intercellular Ca^2+^ waves have been involved in key cancer-related process including escape from apoptosis, perpetuation of growth and metastasis ([@bib31]). Particularly, higher intracellular Ca^2+^ concentrations favour cell proliferation by promoting remodelling of the actin cytoskeleton ([@bib31]).

Our results also showed that expression of Cx43 in melanoma cells increases both basal and TNF-*α*-induced apoptosis of FMS melanoma cells. Interestingly, FMS-Cx43 metastatic lung tumours displayed higher Cx43-GJ plaques accompanied by active caspase-3. These data are consistent with previous studies showing that restoration of Cx43 expression in tumour cells correlates with the inhibition of tumour growth and expression of genes involved in the regulation of the cell cycle and apoptosis including Bcl-2 and caspase-3/7 ([@bib14]). Additional studies have shown that Cx43 overexpression stimulates apoptotic cell death via GJ-mediated transfer of proapoptotic signals such as Ca^2+^ and IP~3~ between cells ([@bib7]; [@bib21]; [@bib4]). Furthermore, the absence of Cx43 and GJIC correlates with cancer stem cell features and expression of epithelial-to-mesenchymal transition markers in pancreatic cancer cells ([@bib9]), both associated with a higher basal viability, resistance to gemcitabine and enhanced clonogenic potential. Restoration of Cx43 expression and GJIC in melanoma cells could have an effect on proliferation, metastasis and induction of apoptosis through inhibition of its cancer stem cell characteristics ([@bib47]).

Although over 21 different isoforms of Cxs have been characterised in humans, only Cx26 and Cx43 are expressed in melanocytes ([@bib16]; [@bib20]). During melanoma transformation and progression, the expression of Cxs is downregulated, thus promoting loss of communication with cells of the local microenvironment ([@bib16]; [@bib27]). Our results along with recent evidences ([@bib53]; [@bib1]) suggest that Cx43, and not Cx26, can act as a tumour suppressor during melanoma tumorigenesis. Following ectopic expression of GFP-tagged Cx26 and Cx43 in the Cx-deficient B16-BL6 mouse melanoma cell line, expression of Cx43, but not Cx26, significantly reduced cellular proliferation and anchorage-independent growth in these cells ([@bib1]).

The role of Cxs in invasion and metastasis is controversial, and whereas several reports indicate that Cxs may reduce tumour metastasis ([@bib26]; [@bib40]; [@bib3]; [@bib36]; [@bib49]), other studies argue the opposite effect ([@bib32]; [@bib44]). [@bib26] observed that expressing Cx43 in breast cancer cells decreases their metastatic potential through a mechanism independent of GJIC but, rather, related to N-cadherin expression and apoptosis. N-cadherin expression is involved in epithelial-to-mesenchymal transition in cancer cells by impairing cell polarity and cell--cell adhesion, and increasing a more migratory and invasive phenotype ([@bib50]). However, our data point to a role for Cx43 expression regulating the last steps of the metastatic process, when tumour cells have to colonise distant organs such as the lung, and proliferate and survive in this new environment, which requires the reversion of EMT. Furthermore, recent data strongly suggest that Cx43 acts as a tumour suppressor protein, which may predict clinical outcomes in chemotherapy-treated patients of different kind of cancers ([@bib42]; [@bib8]; [@bib49]). Moreover, we recently showed that Cx43 accumulates at the interface between natural killer (NK) cells and melanoma cells, facilitating the NK cell cytotoxic activity against melanoma ([@bib46]), suggesting a putative impact of tumour-Cx43 expression in immunotherapy outcomes from melanoma patients.

In summary, our findings propose an important role for Cx43 controlling melanoma growth and metastasis, likely through a mechanism dependent of GJ communication and induction of apoptosis. Therefore, it is tempting to speculate that the use of drugs that selectively enhance Cx43 expression on tumours and/or melanoma cells ([@bib51]; [@bib5]) could enhance the efficacy of cancer therapies.
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![**Connexin 43 expression in human melanoma cells.** Total Cx43 expression pattern was evaluated by immunofluorescence staining and analysed by flow cytometry (**A**) or confocal microscopy (**B** and **C**) in four different human melanoma cell lines (FMS, HF, DFW and DFB). (**A**) The histogram shows the relative expression of Cx43 in the four human melanoma cell lines. Filled grey histogram correspond to the isotype control staining. (**B**) Representative images of Cx43 (green) distribution. Blue: nucleus staining (Hoechst). The Cx43 accumulated in GJ plaques are indicated with white arrows. Scale bars, 5 *μ*[M]{.smallcaps}. (**C**) Quantification of Cx43 fluorescence signal intensities. \**P*\<0.05; \*\**P*\<0.01.](bjc2015162f1){#fig1}

![**Connexin 43-mediated cell coupling and proliferation level in human melanoma cells.** (**A**) Melanoma cells were preloaded with calcein-AM (GJ-diffusible dye) or Dil-CM (non-GJ-diffusible dye) and cocultured for 60 min in a 1 : 1 ratio (calcein^+^Dil^−^ donor cells : calcein^−^Dil^+^ acceptor cells) in the presence of control (gap20) or inhibitory (1848) Cx43-specific mimetic peptide. The calcein transfer from the Dil^−^ to Dil^+^ cells was assessed by flow cytometry. (**A**, lower panel) Bar graphs show the percentage of calcein^+^Dil^+^ cells and correspond to results from three independent experiments. (**B**) Proliferation was determined by CFSE (carboxyfluorescein succinimidyl ester) dilution and flow cytometry in synchronised melanoma cell cultures. Percentages of proliferating cells are indicated in the representative densities plots and in the bar graphs (*n*=3). (**C**) Nonobese diabetic (NOD)/LtSz-*scid IL2Rγ*^*null*^ mice received a single subcutaneous injection of FMS or DFB (500 000 cells), and the growth of primary tumours was monitored for 15 days (*n*=3 mice per group). The growth curves are statistically different (*P*\<0.01). \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001.](bjc2015162f2){#fig2}

![**Connexin 43 overexpression increases GJ coupling and reduces melanoma cell proliferation.** (**A**--**C**) Connexin 43 expression was measured in FMS cells stably transfected with Cx43 or in control cells (transfected with the control empty vector (EV)) by western blot (**A**), flow cytometry (**B**) or immunofluorescence microscopy (**C**). (**A**) *β*-Actin was used as a loading control. (**B**) Grey histogram corresponds to isotype control. (**C**, left) Cx43 (green)-positive GJ plaque structures are indicated with white arrows. Blue: nucleus staining (Hoechst). Scale bars, 5 *μ*[M]{.smallcaps}. (**C**, right) Bar graphs show the quantification of the Cx43 fluorescence intensities. (**D**) FMS-EV or FMS-Cx43 melanoma cells were preloaded with calcein-AM or Dil-CM and cocultured for 60 min in a 1 : 1 ratio (calcein^+^Dil^−^ donor cells : calcein^−^Dil^+^ acceptor cells) in the presence of control (gap20) or inhibitory (1848) Cx43-specific mimetic peptides. Alternatively, cells were treated with a hemichannel-specific Cx43-mimetic inhibitory peptide (P5). Bar graphs show the percentage of calcein^+^Dil^+^ cells (*n*=3). (**E**) The incorporation of \[^3^H\]thymidine assays were carried out to determine the proliferative rate of two FMS-Cx43 clones (C1 and C2) or the control FMS-EV cells. Cells were cultured in the presence of control gap20 (−) or inhibitory 1848 peptides (+) (*n*=3). \**P*\<0.05; \*\*\**P*\<0.001.](bjc2015162f3){#fig3}

![**Connexin 43 overexpression increases basal and tumour necrosis factor-*α* (TNF-*α*)-induced apoptosis in melanoma cells.** Representative dot plots (**A**) and graphs show the distribution of propidium iodide (PI) and annexin-V (AV) staining in FMS-EV or FMS-Cx43 cells, untreated or treated for 24 h with 200 ng ml^−1^ of TNF-*α*. (**B**) Bar graphs show the early apoptotic (AV^+^PI^−^) or total dying (AV^+^) cells represented as the percentage of positive cells (upper panels) or as fold change relative to untreated cells (lower panels). (**C**) The basal level of early apoptotic (AV^+^PI^−^) or total dying (AV^+^) FMS-Cx43 cells are shown as fold change relative to FMS-EV cells (*n*=3). \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001.](bjc2015162f4){#fig4}

![**Connexin 43 overexpression reduces melanoma tumour growth and prevents metastasis in a xenotransplantation model.** (**A**) Nonobese diabetic NOD/LtSz-*scid IL2Rγ*^*null*^ (NOD/SCID) mice received a single subcutaneous injection of FMS-EV or FMS-Cx43 (500 000 cells), and the growth of primary tumours was monitored for 15 days (*n*=3 mice per group). (**B**) Nonobese diabetic/SCID mice received a single intravenous injection of FMS-EV, FMS-Cx43 (250 000 cells) or PBS (*n*=6 mice per group). The mice were terminated on day 18 after inoculation and the lungs were examined. The graph bar shows the number of metastasis counted in the lungs of six mice per group. Scale bar, 1 cm. (**C**) Immunohistochemical staining of Mart-1 in melanoma lung metastasis biopsies of NOD/SCID mice injected with FMS-EV or FMS-Cx43 cells (overview of six mice per group). Scale bar, 25 *μ*[M]{.smallcaps}. (**D**) Immunofluorescence analysis showed *in vivo* Cx43 expression (green) and Cx43-based GJ formation (white arrows) on melanoma lung metastasis biopsies of NOD/SCID mice injected with FMS-EV or FMS-Cx43 cells. Blue: nucleus staining (Hoechst). Enlarged images (3 × ) marked by the white boxes are shown on the right. Scale bar, 30 *μ*[M]{.smallcaps}. (**E**) Immunohistochemical staining of active caspase-3 (black arrows) in melanoma lung metastasis biopsies of NOD/SCID mice injected with FMS-EV or FMS-Cx43 cells (overview of six mice per group). Below and upper each photograph showed the number of active capsase-3 positive cells per 14 *μ*[M]{.smallcaps}^2^. Scale bar, 60 *μ*[M]{.smallcaps}. \**P*\<0.05; \*\*\**P*\<0.001.](bjc2015162f5){#fig5}
